BIO — Bio-Rad Laboratories, Inc.
CIK 12208 · SEC EDGAR fundamentals
Latest 10-K filed February 13, 2026 · period ending December 31, 2023
Headline figures
Top-line sales for the most-recent fiscal year
FY2025 · 10-K
Profit after all expenses, taxes, interest
FY2025 · 10-K
Net income per diluted share outstanding
FY2025 · 10-K
Cash actually generated by the business
FY2025 · 10-K
Balance sheet
Everything the company owns
FY2025 · 10-K
Everything the company owes
FY2025 · 10-K
Assets minus liabilities (book value)
FY2025 · 10-K
Debt due more than 12 months out
FY2025 · 10-K
Revenue history
Revenue from Contract with Customer, Excluding Assessed Tax · FY values from RevenueFromContractWithCustomerExcludingAssessedTax
| Fiscal year | Revenue | vs prior | Source |
|---|---|---|---|
| FY2025 | $2.67B | -4.7% | 10-K |
| FY2024 | $2.80B | -4.1% | 10-K |
| FY2023 | $2.92B | +14.8% | 10-K |
| FY2022 | $2.55B | +10.1% | 10-K |
| FY2021 | $2.31B | — | 10-K |
Read the source
All figures on this page were filed by Bio-Rad Laboratories, Inc. with the SEC and pulled directly from EDGAR's XBRL CompanyFacts API. Click below to view the latest annual report (10-K) in full.
Open latest 10-K on SEC EDGAR →Data sources & methodology
- SEC EDGAR — official company filings (full-text search) ↗
- SEC EDGAR — institutional Form 13F holdings ↗
- U.S. House Clerk — Periodic Transaction Reports (Congress) ↗
All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →
TZ Researched & published by TradesZ Research
Not investment advice. Figures sourced from the SEC's XBRL CompanyFacts API — public-domain federal records. Companies occasionally restate prior-year numbers; we show the latest filed value per fiscal year.